Sangamo Shoots Up As Regulatory Path Clears For Fabry Gene Therapy

The US group has had a tough year but the signs look more promising for isaralgagene civaparvovec as the FDA agrees on the design for a registrational trial for the gene therapy. Now Sangamo needs to secure a partner.